Pinnacle Spine — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Pinnacle Spine Group is a commercial-stage medical device company specializing in spinal fusion solutions. Founded in 2010, the company has pioneered the InFill® technology platform, a patented system for integrated, in-situ bone graft delivery designed to overcome the limitations of traditional pre-packed implants. Led by President Jim Lynn and Chief Medical Officer Dr. Russell W. Nelson, the company targets the substantial spinal implant market by offering surgeons greater control and aiming to improve fusion success rates. Pinnacle Spine operates as a private, revenue-generating entity with a focused product line in the competitive spine device sector.

Spine DisordersDegenerative Spinal Conditions

Technology Platform

Patented InFill® technology platform featuring interbody fusion implants with integrated, in-situ bone graft delivery systems designed to optimize graft-to-vertebral endplate contact.

Opportunities

The large and growing global spinal implant market, combined with a clear surgical need to improve fusion success rates, presents a significant opportunity.

Demonstrating superior clinical outcomes through its InFill® technology could allow Pinnacle Spine to capture market share from established competitors and potentially become an attractive acquisition target for a larger medical device company seeking innovative spine technology.

Risk Factors

Key risks include intense competition from large, well-resourced medical device corporations, potential challenges in securing favorable insurance reimbursement for its technology, and the execution risks associated with scaling a commercial-stage private company in a capital-intensive industry.

The company's success is highly dependent on surgeon adoption, which can be slow to change in established procedural workflows.

Competitive Landscape

Pinnacle Spine competes in the crowded spinal implant market against giants like Medtronic, Stryker, Johnson & Johnson (DePuy Synthes), and NuVasive, as well as numerous smaller specialized firms. Its differentiation is narrowly focused on the in-situ graft delivery mechanism, whereas competitors compete on broader factors including material science (PEEK, titanium, 3D-printed porous metals), integrated navigation, and expansive procedural portfolios.

More companies in Regenerative Medicine →More companies in United States →